As Esperion Therapeutics (ESPR) Share Value Declined, Sabby Management Has Increased Holding by $1.74 Million; Catalyst Capital Advisors Has Raised Its Enlink Midstream (ENLC) Stake by $595,170

EnLink Midstream, LLC (NYSE:ENLC) Logo

Sabby Management Llc increased its stake in Esperion Therapeutics Inc (ESPR) by 38.45% based on its latest 2018Q4 regulatory filing with the SEC. Sabby Management Llc bought 38,589 shares as the company’s stock declined 11.78% while stock markets rallied. The hedge fund held 138,958 shares of the health care company at the end of 2018Q4, valued at $6.39M, up from 100,369 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.34 billion market cap company. The stock increased 1.71% or $0.84 during the last trading session, reaching $49.87. About 636,695 shares traded or 7.24% up from the average. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 39.96% since March 17, 2018 and is downtrending. It has underperformed by 44.33% the S&P500. Some Historical ESPR News: 22/05/2018 – Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Esperion Therapeutics, Inc; 27/03/2018 – ESPERION STUDY MET PRIMARY ENDPOINT; 07/03/2018 – ESPERION PHASE 3 BEMPEDOIC ACID STUDY MET PRIMARY ENDPOINT; 23/05/2018 – The Klein Law Firm Announces a Class Action Filed on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR); 02/05/2018 – ESPERION MET PRIMARY ENDPOINT OF SAFETY & TOLERABILITY; 23/05/2018 – The Klein Law Firm Announces a Class Action Filed on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff De; 27/03/2018 – Esperion’s cholesterol drug succeeds in mid-stage study; 27/03/2018 – ESPERION PHASE 2 STUDY OF BEMPEDOIC ACID MET PRIMARY ENDPOINT; 09/04/2018 – Investor Expectations to Drive Momentum within Esperion Therapeutics, Celestica, Sapiens International Corporation N.V, Royal B; 22/05/2018 – Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference

Catalyst Capital Advisors Llc increased its stake in Enlink Midstream Llc (ENLC) by 12.76% based on its latest 2018Q4 regulatory filing with the SEC. Catalyst Capital Advisors Llc bought 66,130 shares as the company’s stock rose 0.18% with the market. The institutional investor held 584,443 shares of the public utilities company at the end of 2018Q4, valued at $5.55 million, up from 518,313 at the end of the previous reported quarter. Catalyst Capital Advisors Llc who had been investing in Enlink Midstream Llc for a number of months, seems to be bullish on the $5.89B market cap company. The stock increased 3.51% or $0.41 during the last trading session, reaching $12.09. About 20.60 million shares traded or 565.14% up from the average. EnLink Midstream, LLC (NYSE:ENLC) has declined 23.36% since March 17, 2018 and is downtrending. It has underperformed by 27.73% the S&P500. Some Historical ENLC News: 16/05/2018 – MOODY’S AFFIRMS DEVON ENERGY & ENLINK AT Ba1; 19/03/2018 – EnLink Midstream Expects No Impact to Fincl Results Related to Revised FERC Policy; 27/04/2018 – EnLink Midstream LLC Presenting at Conference May 17; 26/04/2018 – EnLink Midstream LLC Closes Above 50-Day Moving Average; 16/05/2018 – DEVON ENERGY & ENLINK OUTLOOK STABLE BY MOODY’S; 08/05/2018 – EnLink Midstream LLC at Deutsche Bank Conference Tomorrow; 19/04/2018 – DJ EnLink Midstream LLC, Inst Holders, 1Q 2018 (ENLC); 19/03/2018 – ENLINK MIDSTREAM SEES NO IMPACT ON REVISED FERC POLICY; 16/05/2018 – Report: Developing Opportunities within Pacific Premier, EnLink Midstream, CENTENNIAL RES, Navistar International, National Fue; 01/05/2018 – Enlink Midstream 1Q EPS 6c

Sabby Management Llc, which manages about $835.79M and $454.57 million US Long portfolio, decreased its stake in Fibrogen Inc (Put) by 529 shares to 915 shares, valued at $4.24M in 2018Q4, according to the filing. It also reduced its holding in Viking Therapeutics Inc (Call) by 440 shares in the quarter, leaving it with 100 shares, and cut its stake in Astrazeneca Plc (Put).

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Seekingalpha.com which released: “Esperion completes marketing applications for bempedoic acid – Seeking Alpha” on February 28, 2019, also Nasdaq.com with their article: “Notable Wednesday Option Activity: TWTR, FSLR, ESPR – Nasdaq” published on September 12, 2018, Nasdaq.com published: “Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 – Nasdaq” on March 01, 2019. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Globenewswire.com and their article: “Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) – GlobeNewswire” published on February 22, 2019 as well as Nasdaq.com‘s news article titled: “Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine – Nasdaq” with publication date: March 13, 2019.

Investors sentiment decreased to 1 in 2018 Q4. Its down 0.11, from 1.11 in 2018Q3. It turned negative, as 22 investors sold ESPR shares while 40 reduced holdings. 23 funds opened positions while 39 raised stakes. 24.06 million shares or 2.18% less from 24.60 million shares in 2018Q3 were reported. C Worldwide Grp Inc Holdg A S reported 4,874 shares or 0% of all its holdings. Hsbc Public Ltd Limited Liability Company holds 0.02% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 240,590 shares. Ubs Asset Mngmt Americas has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Ameritas Ptnrs Incorporated has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Hamilton Lane Advisors Lc holds 0.87% or 21,562 shares in its portfolio. Nicholas Inv Limited Partnership stated it has 8,353 shares. Paloma Prns Management stated it has 4,500 shares. Morgan Stanley holds 0% or 196,890 shares in its portfolio. The Utah-based Wasatch Advsr has invested 0.34% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). State Of Wisconsin Inv Board holds 23,400 shares or 0% of its portfolio. Bancorporation Of Mellon Corp holds 104,205 shares. Parametric Portfolio Assocs Limited Liability Company reported 20,420 shares stake. State Of New Jersey Common Pension Fund D reported 0.01% stake. Metropolitan Life Ins New York reported 7,698 shares. Gilder Gagnon Howe Lc, New York-based fund reported 1,600 shares.

Catalyst Capital Advisors Llc, which manages about $653.50M and $2.68 billion US Long portfolio, decreased its stake in Walker & Dunlop Inc (NYSE:WD) by 15,200 shares to 900 shares, valued at $39,000 in 2018Q4, according to the filing. It also reduced its holding in Paypal Hldgs Inc by 261,476 shares in the quarter, leaving it with 5,755 shares, and cut its stake in Tallgrass Energy Gp Lp.

More important recent EnLink Midstream, LLC (NYSE:ENLC) news were published by: Prnewswire.com which released: “Cushing® Asset Management and Swank Capital Announce Rebalancing of The Cushing® Utility Index – PRNewswire” on February 21, 2019, also Globenewswire.com published article titled: “Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics — New Research Emphasizes Economic Growth – GlobeNewswire”, Benzinga.com published: “Sell-Side Reacts To EnLink Midstream’s Proposed MLP Buyout (NYSE:ENLC)(NYSE:ENLK) – Benzinga” on October 23, 2018. More interesting news about EnLink Midstream, LLC (NYSE:ENLC) was released by: Benzinga.com and their article: “Earnings Scheduled For February 19, 2019 – Benzinga” with publication date: February 19, 2019.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart